- US-listed companies
- Viking Therapeutics, Inc.
- Income statement
Viking Therapeutics, Inc.VKTX
Market cap
$4B
P/E ratio
| 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & development | 7 | 9 | 14 | 19 | 24 | 32 | 45 | 54 | 64 | 102 |
| Operating margin (%) | - | - | - | - | - | - | - | - | - | - |
| Operating income | -11,996,478 | -13,847,275 | -19,070,189 | -26 | -33 | -43 | -56 | -70 | -101 | -151 |
| Operating expenses | 12 | 14 | 19 | 26 | 33 | 43 | 56 | 70 | 101 | 151 |
| Net income | -23,403,988 | -14,731,822 | -20,577,665 | -22 | -26 | -39 | -55 | -69 | -86 | -110 |
| Net income margin (%) | - | - | - | - | - | - | - | - | - | - |
| Earnings per share | - | - | - | - | - | - | - | -0.9 | -0.91 | -1.01 |
| Diluted EPS | - | - | - | - | - | - | - | -0.9 | -0.91 | -1.01 |